Patents by Inventor Alain Philippe Vasserot

Alain Philippe Vasserot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-IL-6 antibodies, compositions, methods and uses
    Patent number: 8226611
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: July 24, 2012
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • Anti-IL-6 Antibodies, Compositions, Methods and Uses
    Publication number: 20120045453
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: October 27, 2011
    Publication date: February 23, 2012
    Inventors: YAN CHEN, DEBRA GARDNER, DAVID M. KNIGHT, MICHAEL W. LARK, BAILIN LIANG, DAVID J. SHEALY, XIAO-YU R. SONG, VEDRANA STOJANOVIC-SUSULIC, RAYMOND W. SWEET, SUSAN H. TAM, SHENG-JIUN WU, JING YANG, DAVID MATTHEW MARQUIS, ERIC MICHAEL SMITH, ALAIN PHILIPPE VASSEROT
  • Methods of treating conditions using anti-IL-6 antibodies
    Patent number: 8067003
    Abstract: Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: November 29, 2011
    Assignees: Centocor, Inc., Applied Molecular Evolution, Inc.
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • Methods of Diagnosing and Treating Conditions Using Anti-IL-6 Antibodies
    Publication number: 20110081355
    Abstract: Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.
    Type: Application
    Filed: October 8, 2010
    Publication date: April 7, 2011
    Inventors: YAN CHEN, DEBRA GARDNER, DAVID M. KNIGHT, MICHAEL W. LARK, BAILIN LIANG, DAVID J. SHEALY, XIAO-YU R. SONG, VEDRANA STOJANOVIC-SUSULIC, RAYMOND W. SWEET, SUSAN H. TAM, SHENG-JIUN WU, JING YANG, DAVID MATTHEW MARQUIS, ERIC MICHAEL SMITH, ALAIN PHILIPPE VASSEROT
  • Anti-IL-23 antibodies
    Patent number: 7872102
    Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: January 18, 2011
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Craig Duane Dickinson, Kristine Kay Kikly, David Matthew Marquis, Alain Philippe Vasserot
  • Anti-IL-6 antibody nucleic acid molecules and methods
    Patent number: 7833755
    Abstract: Anti-IL-6 antibody nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: November 16, 2010
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • ANTI-EGFR ANTIBODIES
    Publication number: 20100166755
    Abstract: The present invention encompasses EGFR specific monoclonal antibodies, or antigen-binding portions thereof. These antibodies, or antigen-binding portions thereof, have high affinity for EGFR, inhibit the activation of EGFR, and are useful for the treatment of EGFR mediated cancers.
    Type: Application
    Filed: March 12, 2010
    Publication date: July 1, 2010
    Applicant: APPLIED MOLECULAR EVOLUTION
    Inventors: Catherine Brautigam BEIDLER, Alain Philippe Vasserot, Jeffry Dean Watkins
  • Anti-EGFR antibodies
    Patent number: 7723484
    Abstract: The present invention encompasses EGFR specific monoclonal antibodies, or antigen-binding portions thereof. These antibodies, or antigen-binding portions thereof, have high affinity for EGFR, inhibit the activation of EGFR, and are useful for the treatment of EGFR mediated cancers.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: May 25, 2010
    Assignee: Applied Molecular Evolution, Inc.
    Inventors: Catherine Brautigam Beidler, Alain Philippe Vasserot, Jeffry Dean Watkins
  • Humanized anti-IL-1 beta antibodies
    Patent number: 7714120
    Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, osteoarthritis, or neuroinflammation.
    Type: Grant
    Filed: April 23, 2009
    Date of Patent: May 11, 2010
    Assignee: Applied Molecule Evolution, Inc.
    Inventors: Craig Duane Dickinson, Alain Philippe Vasserot, Jeffry Dean Watkins, Jirong Lu
  • THROMBOPOIETIC ACTIVITY OF TYROSYL-TRNA SYNTHETASE POLYPEPTIDES
    Publication number: 20100092434
    Abstract: Thrombopoietic compositions are provided comprising tyrosyl tRNA synthetase polypeptides, including truncations and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from increased thrombopoiesis, such as thrombocytopenia.
    Type: Application
    Filed: June 10, 2009
    Publication date: April 15, 2010
    Applicant: ATYR PHARMA, INC.
    Inventors: Rajesh Belani, Jeffry Dean Watkins, Wei Zhang, Alain Philippe Vasserot
  • Anti-IL-23 Antibodies
    Publication number: 20090240036
    Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.
    Type: Application
    Filed: August 23, 2006
    Publication date: September 24, 2009
    Applicant: ELI LILLY AND COMPANY
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Craig Duane Dickinson, Kristine Kay Kikly, David Matthew Marquis, Alain Philippe Vasserot
  • Anti-IL-6 Antibody Nucleic Acid Molecules and Methods
    Publication number: 20090239258
    Abstract: Anti-IL-6 antibody nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: May 22, 2009
    Publication date: September 24, 2009
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • HUMAN IL-1 BETA ANTAGONISTS
    Publication number: 20090209004
    Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, osteoarthritis, or neuroinflammation.
    Type: Application
    Filed: April 23, 2009
    Publication date: August 20, 2009
    Inventors: Craig Duane Dickinson, Alain Philippe Vasserot, Jeffry Dean Watkins, Jirong Lu
  • METHODS OF OPTIMIZING ANTIBODY VARIABLE REGION BINDING AFFINITY
    Publication number: 20090202986
    Abstract: The present invention provides optimized heteromeric variable region binding fragments and antibodies comprising optimized heteromeric variable region binding fragments. Preferably, the optimized heteromeric variable region binding fragments exhibit optimized activity compared to donor heteromeric variable regions and have unvaried human frameworks. The present invention also provides methods of making the optimized heteromeric variable region binding fragments.
    Type: Application
    Filed: October 28, 2004
    Publication date: August 13, 2009
    Inventors: William D. Huse, Jeffry Dean Watkins, Alain Philippe Vasserot, David Matthew Marquis, Eric Michael Smith
  • Anti-il-6 antibodies, compositions, methods and uses
    Patent number: 7560112
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: July 14, 2009
    Assignees: Applied Molecular Evolution, Inc., Centocor Ortho Biotech Inc.
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • Humanized anti-IL-1? antibodies
    Patent number: 7541033
    Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, osteoarthritis, or neuroinflammation.
    Type: Grant
    Filed: January 21, 2004
    Date of Patent: June 2, 2009
    Assignee: Applied Molecular Evolution, Inc.
    Inventors: Craig Duane Dickinson, Alain Philippe Vasserot, Jeffry Dean Watkins, Jirong Lu
  • Humanized anti-ghrelin antibodies
    Patent number: 7479271
    Abstract: Humanized antibodies, or antigen-binding portions thereof, that preferentially bind acylated ghrelin with respect to unacylated ghrelin, are disclosed. These molecules have high affinity and a slow off rate for acylated ghrelin, and neutralize acylated ghrelin activity. These antibodies, or antigen-binding portions thereof, are useful for neutralizing acylated ghrelin activity, e.g., in a subject suffering from a disorder in which ghrelin activity is detrimental, such as obesity.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: January 20, 2009
    Assignee: Eli Lilly and Company
    Inventors: David Matthew Marquis, Alain Philippe Vasserot, Derrick Ryan Witcher
  • Anti-Egfr Antibodies
    Publication number: 20080274114
    Abstract: The present invention encompasses EGFR specific monoclonal antibodies, or antigen-binding portions thereof. These antibodies, or antigen-binding portions thereof, have high affinity for EGFR, inhibit the activation of EGFR, and are useful for the treatment of EGFR mediated cancers.
    Type: Application
    Filed: November 6, 2006
    Publication date: November 6, 2008
    Inventors: Catherine Brautigam Beidler, Alain Philippe Vasserot, Jeffry Dean Watkins
  • Telomerase Promoter Sequences for Screening Telomerase Modulators
    Publication number: 20080220438
    Abstract: Telomerase reverse transcriptase is part of the telomerase complex responsible for maintaining telomere length and increasing the replicative capacity of progenitor cells. Telomerase activity is turned off in mature differentiated cells, but is turned back on again in hyperplastic diseases, including many cancers. This disclosure provides regulatory elements that promote transcription in cells that express telomerase reverse transcriptase (TERT).
    Type: Application
    Filed: April 25, 2008
    Publication date: September 11, 2008
    Inventors: Gregg B. Morin, Serge Lichtsteiner, Alain Philippe Vasserot, Robert Adams, William H. Andrews
  • Anti-IL-6 antibodies, compositions, methods and uses
    Patent number: RE43672
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: September 18, 2012
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chan, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot